Ferring Ventures

Ferring Ventures is a private investment firm specializing in the development of innovative therapies in areas of unmet medical need. Based in Kuopio, Finland, the firm focuses on advancing cutting-edge cell therapy research and development to improve patient outcomes through groundbreaking therapies for cancer. Ferring Ventures collaborates with academic institutions, contract research organizations, contract development and manufacturing organizations, and regulatory teams to ensure a product path from research to patients. The firm's main therapeutic focus is cancer, but its scope of interest is not fixed, and it is also evaluating other disease areas. Ferring Ventures is a subsidiary of Ferring Pharmaceuticals, a Swiss multinational biopharmaceutical company specializing in areas such as reproductive health, maternal health, gastroenterology, and urology. Ferring Pharmaceuticals has been developing treatments for mothers and babies for over 50 years and has its own operating subsidiaries in more than 50 countries, marketing its products in over 100 countries. Ferring Ventures' mission is to conduct high-level research in the translational field of cell therapy, providing an exciting environment for applied research of Advanced Therapy Medicinal Products (ATMPs), discovering, establishing, and developing them through Phase I/IIa clinical trials, and utilizing some of the most advanced analytical and mechanistic proof-of-principle approaches in the sector. The firm is committed to advancing innovative cell therapy solutions for cancer patients and is actively involved in collaborations to enhance the development and production of these therapies. For example, in October 2024, Ferring Ventures and the University of Eastern Finland announced the continuation of their research agreement focusing on cell therapy, aiming to accelerate the development of new precision medicine treatments. This partnership combines the university's cutting-edge research capabilities with Ferring Ventures' industry expertise to address a wide range of medical conditions and offer new hope to patients with unmet clinical needs. Ferring Ventures' dedication to innovation and collaboration underscores its commitment to improving patient outcomes through the development of advanced cell and gene therapies.

Focus on innovative therapies in areas of unmet medical need, Collaboration with academic institutions and research organizations, Commitment to advancing cell and gene therapies, Interest in oncology and other disease areas, Engagement in Phase I/IIa clinical trials, Utilization of advanced analytical and mechanistic approaches, Alignment with Ferring Pharmaceuticals' mission and values, Geographical focus on Europe, North America, and Asia, Willingness to engage in long-term partnerships, Capacity to support translational research and development